Oncology

“Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016” – A DelveInsight Report

Posted on

DelveInsight, the leading market research and consulting company has added a new report “Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016” to its portfolio.

The Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report provides the client with details on the ongoing enterprises and the upcoming business opportunities related to new interventions. It comprehensively includes:

Information on 215+ products and 50+ different technologies along with 70+ companies actively involved in drug development. There are 5 drugs in phase III, 22 in phase II, 42 in phase I, and 87 in pre-clinical, 28 in discovery, 16 dormant and 19 discontinued drugs.

Brentuximab Vedotin,developed by Seattle Genetics, is the leading product.

R&D activities and technologies used along with the pipeline molecules in development.

Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.

Information related to collaborations, in-licensing and out-licensing deals.

DelveInsights, Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report provides the in-depth analysis of Antibody Drug Conjugate Landscape across the globe. Therefore the report on Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape provide information on chemical, technology information and comparative analysis at various stages. In addition, it helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 2950 as a single user license, USD 5900 as a site license and USD 8850 as a Global/Enterprise License.

For more information on Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report, email at info@delveInsight.com

About Us:

DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

Advertisements

PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2016 -A DelveInsight Report

Posted on Updated on

DelveInsight has made strong presence in Oncology market with 100+ Reports on Oncology based Indications & Mechanism of Action (MOA). DelveInsight Report, PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2016 has received great response and feedback from clients.
PD-1and PDL-1 is the next targeted agents in Oncology. These therapies have the enormous potential to treat cancer and have an excellent response in the increasing number of patients. Many experts say that out of all of the therapies, PD-1/PD-L1 inhibitors look to be the most promising in treating cancer.
Reports Highlights:
  • PD-1 and PD-L1 Inhibitors Therapy Pipeline scenario
  • Collaborations & partnering deals
  • Current Prominent Research Areas and Key Players
  • Pipeline product profiles PD-1 and PD-L1 Inhibitors Technologies
  • Market Drivers and Barriers
Report Coverage:
40+ products, 30+ companies and 15+ different technologies
PD-1/PDL-1 Inhibitors report provides the analysis on the worldwide therapeutic market of PD-1 and PD-L1 inhibitors. In addition, the report provides the development of combinations therapies with Immune-check point Inhibitors (PD-1 and PD-L1) along with the information on ongoing collaborations for the development of combinations regimens.
 PD-1/PDL-1 Inhibitors report report covers the therapeutics assessment of pipeline molecules by mechanism of action (MoA), route of administration (RoA), molecule type, along with latest updates. The reports also cover Commercial Aspects such as the Current and Future Market, market drivers and barriers followed by SWOT Analysis
The Reports will help you to identify emerging players with potentially strong product information, licensing opportunities and helps you to create effective counter-strategies to gain competitive advantage.
DelveInsight is offering the Report at a price of USD 2,950 as a single user license, USD 5,900 as a site license andUSD 8,850 as a Global/Enterprise License.
For more information mail us at info@delveinsight.com
About Us:
DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists- Pipeline Insights, 2016 – A DelveInsight Report

Posted on

DelveInsight, the leading market research and consulting company has added new report “LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists- Pipeline Insights, 2016” to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date information of market till date order has been placed.

The report provides the in-depth analysis of the pipeline assets across the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists. The Report gives insights on 30+ products with 15+ different technologies. It also includes around 20+ companies which are active in this field. DelveInsight’s, LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists- Pipeline Insights, 2015 Report covers the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists related therapeutic assessments by molecule type, route of administration, monotherapy and combination products.

The Report also highlights the discontinued and inactive projects in pipeline for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists.

This Report will help you to identify emerging players with potentially strong product information, licensing opportunities and helps you to create effective counter-strategies to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 3,750 as a Global/Enterprise License.

For more information on Pipeline Insight Reports, email at info@delveInsight.com

Contact Us:

DelveInsight Business Research

New Delhi-110075, India

Phone: +91-11-45689769, +91 9650213330

Website: http://delveinsight.com

About Us

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

DelveInsight’s Market Research Reports, 2016

Posted on Updated on

DelveInsight has established its strong presence in therapeutic areas and has launched Analytical Reports on indication, mechanism of actions, drugs, Global API Manufacturers and specialized Reports on Gene Therapy, Anticoagulants, PD-1 and PDL-1, CART and Antibody Drug conjugates.

After tremendous success last year, Delve Insight – Business Consulting & Market Research Company is back again with 2016 updated edition of reports.

Moving forward, this year DelveInsight has broached into new report verticals –Epidemiology and Market Insights in its portfolio.

In addition to that we have also entered into consulting services/custom projects as per interest area of the clients.

DelveInsight’s consulting services includes Market Assessment (Market Size, Market Forecasting and Epidemiology for Indications) & Development Strategies, Competitive Intelligence & Landscaping and Licensing Opportunities.

About Us:

DelveInsight is a leading Business Consulting and Market Research Firm. DelveInsight helps clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

“Endometrial Cancer – Pipeline Insights, 2015”- A DelveInsight’s Report

Posted on Updated on

DelveInsight, the leading market research and consulting company has added a new report “Endometrial Cancer – Pipeline Insights, 2015” to its portfolio. With this launch DelveInsight now has 700+ Reports on Indication Pipeline Insight. In addition to this, our research expertise provides our clients with up to date information of market till the date of order.

The Endometrial Cancer – Pipeline Insights, 2015 report provides client with details on the ongoing enterprises and the upcoming business opportunities related to new interventions.

Untitled

Key Highlights of the Report:

  • The report gives information of 35+ pipeline drugs with 30+ companies actively involved in drug development. There are 7 drugs which are in pre-clinical phase, 10 in phase I, 8 in phase I/II and 11 in phase II.
  • Aeterna Zentaris is developing a lead product Zoptarelin doxorubicin which is in Phase III.
  • R&D activities and technologies used along with the pipeline molecules in development.
  • Stages of development of pipeline molecules.
  • Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.
  • Information related to collaborations, in-licensing and out-licensing deals.

DelveInsights, Endometrial Cancer-Pipeline Insights, 2015 report provides Endometrial Cancer Landscape across the globe. Therefore the report on Endometrial Cancer-Pipeline Insights provides information on chemical, technology information and comparative analysis at various stages. In addition, it helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.

For more information on Pipeline Insight Reports, email at info@delveInsight.com

About Us

DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

DelveInsight’s Indication Active Pharmaceutical Ingredient (API) Reports– 2015

Posted on

DelveInsight expertise over 400+ Indication Active Pharmaceutical Ingredient (API) Reports

Indication-API Insights

DelveInsight, leading Market Research and Business Consulting firm has an expertise in providing business solutions to Pharma and biotech companies. DelveInsight has 400+ Indication API reports on wide range of therapeutic area such as Oncology, Cardiovascular disease, and Autoimmune disorders and Infectious disease.

DelveInsight’s Indication API insight report provides global competitive and therapeutic assessment on marketed drugs, API manufacturers, patent expiration and exclusivity. The report gives clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries. These Reports gives complete information on marketed drugs along with Global API Manufacturers and regulatory filings across Europe, US, India and China. It gives information of global Market therapeutics scenario, regulatory information, marketing status and detail of product profiles for marketed products with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical description. The Report also provides Global drug sales forecast up to 2016.

The Reports give opportunities to generic manufacturers and also helps API industry to track closest competitors and prioritizing new drug intermediates to add to the portfolio when drug goes off patent. The Indication API insight report helps to identify the strategic drivers and market opportunities.

DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.

For more information on API insight Reports, email at info@delveInsight.com

About us

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Website Link: http://delveinsight.com/

Chimeric Antigen Receptor (CAR) T-cell Therapy Landscape; A Report

Posted on Updated on

In the field of oncology, no other approach is as attentive as Immunotherapy. Renewed interest in immunotherapy CAR-Thas been driven by Chimeric Antigen Receptor (CAR) T-cell therapy. This emerging approach is (CAR) T-cell technology which is showing great promise in immunotherapy. There are 35+ products in pipeline and 40+ companies are active in this field.

With the advancement of (CAR) T-cell technology showing more safety and efficacy, the companies dealing with immunotherapy are grabbing the opportunity to enter in this new emerging market by the routes of collaborations and acquisitions.

What is CAR-T Cell Therapy?

CAR T-cells are the engineered T-cells to express chimeric antigen receptor (CARs) which identifies specific antigens of a target-cell. CARs are specifically designed receptors, which graft specificity into an immune effector cell. This therapy acts as genetic modification of T-cells from cancer patients by gene transfer of chimeric antigen receptors (CARs) to recognize molecules on cancer cells without relying on MHC presentation. This adoptive T-cell therapy harnesses the power of the immune system to target and kill tumor cells.

CAR-T Therapy Landscape

Technology

Most of the companies are dealing with the conventional CAR T-cell technology, targeting CD19 antigen of lymphoma cells, which is occupying more than 50% share in target antigens. Meanwhile, the companies are also investing on the studies targeting 25+ different antigens of cancer cells as well as the firms are coming up with 8+ different technologies to enhance the safety and efficacy of the CAR T-cell therapy.

Attractive Pipeline

There are 35+ pipeline products and 40+ companies including small and big firms are actively involved. Out of 40 companies, 15+ leading companies are involved with their product in clinical phases. Novartis with the Phase-II product CTL019 is leading the race.

Partnerships

With 25+ collaborations happened in recent years, Juno Therapeutics (JUNO) has inked a massive $727 million R&D deal with Editas Medicine that is considered as greatest deal in this segment. 7+ Research institutes and 12+ small firms having core CAR T-cell technologies partnered with some of the leading companies for the development of the CAR-T cell therapy.

Indications

As CAR-T technology are showing most promising results in cancer studies, companies are conducting their Pre-clinical and clinical trial studies with 18+ Oncology indications, in which B-cell malignancies, Lymphoma & Leukemia are the prominent one.

CAR-T Cells Therapy Info-graph

CAR-T Therapy

DelveInsight Expert Comments

CAR T-cell therapy will drive the future of Immunotherapy to promising heights. The companies with lagging attention to this approach are already behind. The deals will continue to increase the market size and continued desperation to get on surviving with the key risks on this competitive landscape, numerous players could end up basking in reflected glory.

Written by Vikas Soni, Trainee at DelveInsight

Upcoming DelveInsight Report on CAR-T Cell Therapies-Landscape, 2015

For more information on this Report, mail us at info@delveinsight.com

Lets share our knowledge, provide your comments in the comment section